JP2015512923A5 - - Google Patents

Download PDF

Info

Publication number
JP2015512923A5
JP2015512923A5 JP2015504946A JP2015504946A JP2015512923A5 JP 2015512923 A5 JP2015512923 A5 JP 2015512923A5 JP 2015504946 A JP2015504946 A JP 2015504946A JP 2015504946 A JP2015504946 A JP 2015504946A JP 2015512923 A5 JP2015512923 A5 JP 2015512923A5
Authority
JP
Japan
Prior art keywords
cushing
combination
combination according
syndrome
disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2015504946A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015512923A (ja
JP6383352B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2013/057515 external-priority patent/WO2013153129A1/en
Publication of JP2015512923A publication Critical patent/JP2015512923A/ja
Publication of JP2015512923A5 publication Critical patent/JP2015512923A5/ja
Application granted granted Critical
Publication of JP6383352B2 publication Critical patent/JP6383352B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2015504946A 2012-04-12 2013-04-10 ソマトスタチンアナログの11ベータ−水酸化酵素阻害剤との組合せ Active JP6383352B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261623117P 2012-04-12 2012-04-12
US61/623,117 2012-04-12
PCT/EP2013/057515 WO2013153129A1 (en) 2012-04-12 2013-04-10 Combination of somatostatin-analogs with 11beta-hydroxylase inhibitors

Publications (3)

Publication Number Publication Date
JP2015512923A JP2015512923A (ja) 2015-04-30
JP2015512923A5 true JP2015512923A5 (enExample) 2016-05-19
JP6383352B2 JP6383352B2 (ja) 2018-08-29

Family

ID=48289057

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015504946A Active JP6383352B2 (ja) 2012-04-12 2013-04-10 ソマトスタチンアナログの11ベータ−水酸化酵素阻害剤との組合せ

Country Status (13)

Country Link
US (1) US9333234B2 (enExample)
EP (1) EP2836228B1 (enExample)
JP (1) JP6383352B2 (enExample)
KR (1) KR102136214B1 (enExample)
CN (1) CN104321074B (enExample)
AU (1) AU2013246908B2 (enExample)
BR (1) BR112014025058B1 (enExample)
CA (1) CA2869442C (enExample)
ES (1) ES2980806T3 (enExample)
IN (1) IN2014DN09240A (enExample)
MX (1) MX362533B (enExample)
RU (1) RU2663455C2 (enExample)
WO (1) WO2013153129A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA33904B1 (fr) * 2010-01-14 2013-01-02 Novartis Ag Utilisation d'un agent de modification d'hormones surrénaliennes
TWI707682B (zh) * 2014-07-07 2020-10-21 瑞士商瑞科戴迪股份有限公司 醫藥劑型
WO2016048984A1 (en) * 2014-09-25 2016-03-31 Cortendo Ab (Publ) Methods and compositions for the treatment of cushing's syndrome using 2s, 4r ketoconazole
KR102197526B1 (ko) 2016-01-19 2020-12-31 코어셉트 쎄라퓨틱스 인코포레이티드 이소성 쿠싱 증후군의 감별 진단

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1334742A (zh) * 1998-07-30 2002-02-06 研究及应用科学协会股份有限公司 促生长素抑制素类似物兰瑞肽的应用方法
RU2259375C2 (ru) * 2001-04-09 2005-08-27 Дзе Администрейторс Оф Дзе Тьюлейн Эдьюкейшнл Фанд Агонисты соматостатина
GT200600381A (es) * 2005-08-25 2007-03-28 Compuestos organicos
CN102666535B (zh) * 2009-11-30 2015-02-25 诺华股份有限公司 作为醛固酮合酶抑制剂的咪唑衍生物
MA33904B1 (fr) * 2010-01-14 2013-01-02 Novartis Ag Utilisation d'un agent de modification d'hormones surrénaliennes
WO2013131879A1 (en) * 2012-03-07 2013-09-12 Novartis Ag New application for pasireotide

Similar Documents

Publication Publication Date Title
JP2010270124A5 (enExample)
JP2014528901A5 (enExample)
JP2016530280A5 (enExample)
WO2009043476A3 (en) Neuromedin s as a therapeutic agent
JP2020521797A5 (enExample)
JP2012255026A5 (enExample)
JP2016510326A5 (enExample)
WO2009043448A3 (en) Neuromedin u-25 and neuromedin s as therapeutic agents
JP2016508134A5 (enExample)
JP2014077003A5 (enExample)
RU2016141570A (ru) Комбинации ингибитора fgfr и ингибитора igf1r
JP2016516016A5 (enExample)
JP2015522018A5 (enExample)
JP2017532343A5 (enExample)
JP2013543491A5 (enExample)
EA201270144A1 (ru) Комбинированная терапия при лечении диабета
HK1206246A1 (en) Use of high dose laquinimod for treating multiple sclerosis
JP2013541583A5 (enExample)
JP2015532293A5 (ja) 糖尿病患者における心不全の治療用組成物
JP2015512923A5 (enExample)
JP2015516419A5 (enExample)
JP2015522603A5 (enExample)
JOP20200064A1 (ar) تحضير صور جرعة صلبة تشتمل على أجسام مضادة بعمل طبقات من المحلول/ المعلق
WO2009033722A8 (en) Use of a octreotide as a therapeutic agent
RU2014145351A (ru) КОМБИНАЦИЯ АНАЛОГОВ СОМАТОСТАТИНА С ИНГИБИТОРАМИ 11β-ГИДРОКСИЛАЗЫ